0001140361-19-013355.txt : 20190724 0001140361-19-013355.hdr.sgml : 20190724 20190724160108 ACCESSION NUMBER: 0001140361-19-013355 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190722 FILED AS OF DATE: 20190724 DATE AS OF CHANGE: 20190724 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38978 FILM NUMBER: 19970966 BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 form4.xml FORM 4 X0306 4 2019-07-22 true 0001680581 Fulcrum Therapeutics, Inc. FULC 0001131399 GLAXOSMITHKLINE PLC 980 GREAT WEST ROAD BRENTFORD MIDDLESEX X0 TW8 9GS UNITED KINGDOM true Common Stock 2019-07-22 4 C 0 1785714 A 1785714 I See Footnote Series B Preferred Stock 2019-07-22 4 C 0 12500000 0 D Common Stock 1785714 0 I See footnote On July 22, 2019 upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock converted into Common Stock on a seven-for-one basis without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the IPO. The shares had no expiration date. The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). /s/ Victoria Whyte Authorized Signatory GlaxoSmithKline plc 2019-07-24